latest update:
[TrialBase DB]

trial summary · NCT06948084

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Multiple Myeloma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06948084phase PHASE2enrollment 80start 2027-05-22

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial compares the effect of the combination of daratumumab-hyaluronidase (daratumumab) and teclistamab to the usual treatment of daratumumab, pomalidomide, dexamethasone or daratumumab, carfilzomib and dexamethasone in treating patients with multiple myeloma that has not responded to previous treatment (refractory) or that has come back after a period of improvement (relapsed). Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen, a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Pomalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Carfilzomib, a type of proteasome inhibitor, blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. Giving daratumumab and teclistamab may be more effective than the usual …

Source record: https://clinicaltrials.gov/study/NCT06948084

Facts

registry idNCT06948084
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionRecurrent Multiple Myeloma
sponsorNational Cancer Institute (NCI)
sponsor classNIH
enrollment80
start date2027-05-22
primary completion2028-02-28
completion2028-02-28
results postednot reported

Conditions

  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma

Interventions

  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Carfilzomib
  • Computed Tomography
  • Daratumumab and Recombinant Human Hyaluronidase
  • Dexamethasone
  • FDG-Positron Emission Tomography
  • Pomalidomide
  • Teclistamab

Countries

  • United States

Intervention types: DRUG, PROCEDURE

Work with this record